Ligand Pharmaceuticals Disposes Of Promacta, Plunges 13 Percent

Ligand Pharmaceuticals Inc. (LGND) disposes of Promacta, shares plunge 13 percent, hit 2-year low

“…the company faces it biggest existential threat in what is likely to be a momentous impairment of its largest royalty generating asset, Promacta,”

David Einhorn Buys Three New Stocks: These Are The Names And Theses (Q3 Letter)

david einhorn, reading, valuewalk, internet, investment research, Greenlight Capital, hedge funds, Greenlight Masters, famous hedge fund owners, big value investors, websites, books, reading financials, investment analysis, shortselling, investment conferences, shorting, short biasDavid Einhorn's Greenlight Capital funds returned 5.9% in the third quarter of 2020, compared to a gain of 8.9% for the S&P 500 in the same period. This year has been particularly challenging for value investors. Growth stocks have surged as value has struggled. For Greenlight, one of Wall Street's most established value-focused investment funds, Read More


Fr. Emmanuel Lemelson, June 16, 2014 Research Report

Get The Full Series in PDF

Get the entire 10-part series on Charlie Munger in PDF. Save it to your desktop, read it on your tablet, or email to your colleagues.

Q4 hedge fund letters, conference, scoops etc

Shares of Ligand Pharmaceuticals continued its downward spiral, plunging 13 percent in early trading today, March 6, 2019, falling as much as 63 percent since September 30, 2018 and hitting a 2-year low.

Yesterday after market close the company reported it was disposing its single-largest asset, the 25 year-old Promacta, stating in part:

"We do not control the IP and some of the initial patents come off as early as 2021," (referring to the event as a 'patent cliff')."

The company further stated:

"When it [Promacta] does royalties are expected to quickly diminish significantly... when off patent, the following year the company estimated it could lose over $125 million of revenue,"

In June 2014, Lemelson Capital Management issued its first report pointing out competitive threats to Promacta, its limited future potential as well as the risks associated with Ligand's revenue streams. Since that time, Fr. Emmanuel has publish 4 additional research reports, issued 16 articles/press releases, posted 66 tweets, given 13 interviews, and written two letters to Congress, making nearly 1,000 distinct allegations, including accounting and securities fraud perpetrated by Ligand.

In January 2019 multiple law firms announced investigations into Ligand for possible violations of federal securities laws.

Ligand Pharmaceuticals Inc. (LGND) accounting and securities fraud

On July 17, 2018 Rev. Fr. Emmanuel published an open letter to Congress alleging a multi-year accounting and securities fraud at Ligand Pharmaceuticals the company has since been sued for $3.8 billion by investors.

On August 14, 2014 Lemelson Capital Management, LLC published a report outlining the risk of the bond offering, questioned the representations made by the company, and pointing out that the offering may eventually lead to solvency risks.


Letters to Congress Regarding Ligand:

The Ligand Research Reports:

The Ligand Interviews:

  • Rev. Emmanuel Lemelson of Lemelson Capital Management - #PreMarket Prep for June 19, 2014 
  • Rev. Emmanuel Lemelson, CIO of Lemelson Capital Management - #PreMarket Prep for August 13, 2014
  • Rev Emmanuel Lemelson, CIO of Lemelson Capital Management - #PreMarket Prep for September 16, 2014 
  • Rev. Emmanuel Lemelson, CIO of Lemelson Capital Management - #PreMarket Prep for October 16, 2014
  • Rev. Emmanuel Lemelson, Lemelson Capital Management - #PreMarket Prep for November 18, 2014
  • Rev. Emmanuel Lemelson, CIO of Lemelson Capital Management - #PreMarket Prep for February 20, 2015
  • Rev. Emmanuel Lemelson, Lemelson Capital Management CIO - #PreMarket Prep for March 24, 2015
  • Rev. Emmanuel Lemelson, CIO of Lemelson Capital Management - #PreMarket Prep for April 27, 2015
  • Rev. Emmanuel Lemelson, CIO of Lemelson Capital Management - #PreMarket Prep for June 5, 2015
  • Rev. Emmanuel Lemelson, CIO of Lemelson Capital Management - #PreMarket Prep for August 12, 2015
  • Listen to Fr. Emmanuel live discussing The Amvona Fund, LP and his recent letter to the US Senate